Cover Image
市場調查報告書

轉化生長因子-β1 (TGFB1) :開發中產品分析

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 368726
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
轉化生長因子-β1 (TGFB1) :開發中產品分析 Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 65 Pages
簡介

本報告提供以轉化生長因子-β1 (TGFB1) 為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

轉化生長因子-β1 (TGFB1) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Acceleron Pharma, Inc.
  • Digna Biotech, S.L.
  • Dong Wha Pharma Co., Ltd.
  • Eli Lilly and Company
  • Huabo Biopharm Co., Ltd.
  • Isarna Therapeutics GmbH
  • Johnson & Johnson
  • Novartis AG
  • Scholar Rock, Inc.
  • Sirnaomics, Inc.
  • 大正製藥集團
  • TissueGene, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0777TDB

Summary

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-B1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.

The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transforming Growth Factor Beta 1 (TGFB1) - Overview
    • Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
    • Acceleron Pharma Inc
    • Eli Lilly and Company
    • Genzyme Corp
    • Huabo Biopharm Co Ltd
    • Isarna Therapeutics GmbH
    • Johnson & Johnson
    • Novartis AG
    • Scholar Rock Inc
    • Sirnaomics Inc
  • Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
    • ACE-1332 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fresolimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-1047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-1106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TGF-Beta 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-705 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sulodexide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
    • Featured News & Press Releases
      • May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
      • Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
      • Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
      • Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFB1 Latent Complex
      • Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
      • Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
      • Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
      • Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
      • Mar 27, 2008: Keryx Biopharmaceuticals Announces Termination Of SUN-MACRO Phase 4 Trial
      • Mar 07, 2008: Keryx Biopharmaceuticals Announces That SUN-MICRO Phase 3 Clinical Trial Fails To Meet Primary Efficacy Endpoint
      • Feb 11, 2008: Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
      • Nov 14, 2007: Keryx Announces Positive Final Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For The Treatment Of Diabetic Nephropathy
      • Oct 24, 2007: Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data Presentation On KRX-101 At The Upcoming American Society Of Nephrology Renal Week
      • Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 And Phase 4 Clinical Program Of KRX-101 For Treatment Of Diabetic Nephropathy
      • May 06, 2007: Keryx Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Acceleron Pharma Inc, H1 2017
  • Pipeline by Eli Lilly and Company, H1 2017
  • Pipeline by Genzyme Corp, H1 2017
  • Pipeline by Huabo Biopharm Co Ltd, H1 2017
  • Pipeline by Isarna Therapeutics GmbH, H1 2017
  • Pipeline by Johnson & Johnson, H1 2017
  • Pipeline by Novartis AG, H1 2017
  • Pipeline by Scholar Rock Inc, H1 2017
  • Pipeline by Sirnaomics Inc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Dormant Products, H1 2017 (Contd..2), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top